Eric Coldwell
Stock Analyst at Baird
(5.00)
# 10
Out of 4,818 analysts
185
Total ratings
51.43%
Success rate
118.83%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Outperform | $191 → $194 | $172.84 | +12.24% | 10 | Apr 23, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $221 → $203 | $136.79 | +48.40% | 19 | Mar 4, 2025 | |
| OMI Owens & Minor | Maintains: Neutral | $10 → $11 | $6.47 | +70.02% | 17 | Mar 3, 2025 | |
| AHCO AdaptHealth | Maintains: Outperform | $14 → $16 | $7.45 | +114.91% | 10 | Feb 27, 2025 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $177 → $173 | $106.89 | +61.85% | 13 | Feb 20, 2025 | |
| PINC Premier | Maintains: Neutral | $20 → $19 | $19.57 | -2.91% | 7 | Feb 5, 2025 | |
| MEDP Medpace Holdings | Maintains: Neutral | $354 → $362 | $282.28 | +28.24% | 17 | Jan 27, 2025 | |
| IQV IQVIA Holdings | Maintains: Neutral | $212 → $210 | $143.61 | +46.23% | 16 | Jan 21, 2025 | |
| FTRE Fortrea Holdings | Downgrades: Neutral | $28 → $25 | $5.50 | +354.55% | 7 | Dec 6, 2024 | |
| MCK McKesson | Upgrades: Outperform | $531 → $688 | $695.17 | -1.03% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $282 → $289 | $220.25 | +31.21% | 12 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $137 | $133.69 | +2.48% | 11 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $51 | $10.99 | +364.06% | 16 | Apr 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $54.96 | -18.12% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $65.45 | +0.84% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $1.35 | +3,307.41% | 4 | Nov 10, 2017 |
Quest Diagnostics
Apr 23, 2025
Maintains: Outperform
Price Target: $191 → $194
Current: $172.84
Upside: +12.24%
ICON Public Limited Company
Mar 4, 2025
Maintains: Neutral
Price Target: $221 → $203
Current: $136.79
Upside: +48.40%
Owens & Minor
Mar 3, 2025
Maintains: Neutral
Price Target: $10 → $11
Current: $6.47
Upside: +70.02%
AdaptHealth
Feb 27, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $7.45
Upside: +114.91%
Charles River Laboratories International
Feb 20, 2025
Maintains: Neutral
Price Target: $177 → $173
Current: $106.89
Upside: +61.85%
Premier
Feb 5, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $19.57
Upside: -2.91%
Medpace Holdings
Jan 27, 2025
Maintains: Neutral
Price Target: $354 → $362
Current: $282.28
Upside: +28.24%
IQVIA Holdings
Jan 21, 2025
Maintains: Neutral
Price Target: $212 → $210
Current: $143.61
Upside: +46.23%
Fortrea Holdings
Dec 6, 2024
Downgrades: Neutral
Price Target: $28 → $25
Current: $5.50
Upside: +354.55%
McKesson
Nov 7, 2024
Upgrades: Outperform
Price Target: $531 → $688
Current: $695.17
Upside: -1.03%
Oct 25, 2024
Maintains: Outperform
Price Target: $282 → $289
Current: $220.25
Upside: +31.21%
Aug 15, 2024
Maintains: Outperform
Price Target: $130 → $137
Current: $133.69
Upside: +2.48%
Apr 1, 2022
Downgrades: Neutral
Price Target: $51
Current: $10.99
Upside: +364.06%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $54.96
Upside: -18.12%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $65.45
Upside: +0.84%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $1.35
Upside: +3,307.41%